Our study demonstrated that IFITM3 upregulates MHC-I expression and enhances tumor sensitivity to PD-1 inhibitors in SCLC patients by promoting CD8 + T cell infiltration and cytotoxic. The gene discussed is CD8A; the disease is neoplasm.